LENZ - LENZ Therapeutics Inc

LENZ - LENZ Therapeutics Inc

https://www.lenz-tx.com

Buy Momentum: Bearish

Recent News

Powered by Alpha Vantage

Blindness-Focused LENZ Therapeutics' Investigational Eye Drop Ready To Revolutionize Presbyopia Landscape, Analyst Says - LENZ Therapeutics ( NASDAQ:LENZ )

Benzinga • 1 year, 5 months ago • score: 0.37

Last week, LENZ Therapeutics Inc LENZ released topline results from its Phase 3 CLARITY study of two investigational formulations of aceclidine, LNZ100 and LNZ101.

Interval:

EMA1: EMA2:

AI Tools

Key Metrics

Trend: Range-Bound

As of 2025-09-10 (Snapshot)

None

52W High

$42.08

52W Low

$16.54

MA Status:

50D: Above 200D: Above

Beta (~1 neutral, <0.9 lower risk)

N/A

Valuation

As of 2025-06-30 (Overview)

Trailing P/E (<15 better)

N/A

Forward P/E (<15 better)

N/A

EV/EBITDA (<8 favorable)

-7.99

EV/Revenue (<3 favorable)

197.78

P/S (TTM) (<3 favorable)

239.47

P/B (<3 favorable)

5.80

Ownership

Institution‑heavy

Source: Overview

Insiders (1–5% typical)

2.73%

Institutions (25–75% balanced)

99.84%

Shares Outstanding

28,522,100

Float

13,583,600

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

Profitability: Weak

As of 2025-06-30 (Overview)

Revenue (TTM)

5,000,000

Gross Profit (TTM)

5,000,000

EPS (TTM)

-1.63

Profit Margin (>10% good)

N/A

Operating Margin (TTM) (higher better)

-3.37%

ROE (TTM) (>15% strong)

-0.26%

EPS YoY (Quarterly) (>10% good)

N/A

Revenue YoY (Quarterly) (>8% good)

N/A

Momentum

Bearish momentum

Value

1.8086

Previous

1.8085

Trend

Rising

Signal Cross

No cross

As of

Sep. 12, 2025